Optometry Times

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#620291

United States

#310017

Health/Health

#5531

Traffic sources

Monthly visitors

Articles

Predicting presbyopia reading ADD and progression with AI and machine learning algorithm

2 days ago | optometrytimes.com | AnnMarie Hipsley |Emily Kaiser Maharjan |Sheryl Stevenson |Hattie Hayes

At the 2025 ASCRS meeting in Los Angeles, a concept was shared by AnnMarie Hipsley, DPT, PhD, for optometrists seeking to stay at the forefront of precision ocular care—the Digital Twin. More than a buzzword, a digital twin represents a virtual simulation of a real-world anatomical system, in this case, the human eye.
Takeaways from this week in optometry: May 5 - May 9

5 days ago | optometrytimes.com | Jordana Joy

Takeaways from this week in optometry: May 5 - May 9Catch up on the top stories in optometry during the week of May 5-May 9. Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
ARVO 2025: Rethinking centile growth curves in myopia management with Mark Bullimore, MCOptom, PhD

5 days ago | optometrytimes.com | Mark Bullimore |Martin Harp |Hattie Hayes |Emily Kaiser Maharjan

At the 2025 ARVO conference in Salt Lake City, Mark Bullimore, MCOptom, PhD, of the University of Houston College of Optometry shared a compelling critique of the current use of centile growth curves for axial length in myopia management. Speaking directly to optometrists, Bullimore emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy. Centile growth curves based on general populations are misleading in myopia management.
ARVO 2025: Perfuse Therapeutics announces positive results from phase 1/2a trial of PER-001, an intravitreal implant for glaucoma

6 days ago | optometrytimes.com | Jordana Joy

Biopharmaceutical company Perfuse Therapeutics has announced positive 24-weeks results from its Phase 1/2a trial of PER-001, a first-in-class endothelin antagonist intravitreal implant for glaucoma.1 Data from the completed trial was presented at the Association for Research in Vision and Ophthalmology (ARVO) meeting earlier this week, according to a news release.
Prevent Blindness voices support for reintroduction of EDVI Act

6 days ago | optometrytimes.com | Jordana Joy

Prevent Blindness has vocalized its full support of the recent reintroduced of the Early Detection of Vision Impairments for Children Act (EDVI), or HR 2527, in the US House of Representatives.1 The bipartisan legislation would work to establish grants for states and communities to apply for and access for the implementation of new approaches and improved public education regarding children’s vision, early detection of vision concerns, referrals for eye examinations, and follow-up mechanisms,...
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics

1 week ago | optometrytimes.com | Emily Kaiser Maharjan

Cognition Therapeutics reported topline results for the phase 2 Magnify trial of the oral medication zervimesine intended to slow lesion growth in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD). At 18 months, patients who were treated with zervimesine had 28.6% slower GA lesion growth and their lesions were 28.2% smaller than patients in the placebo growth.
Boehringer Ingelheim kicks off dual phase 2 clinical studies for geographic atrophy candidates

1 week ago | optometrytimes.com | Emily Kaiser Maharjan

Boehringer Ingelheim announced the start of the JADE and VERDANT phase 2 clinical studies to investigate the safety and efficacy of 2 candidates: BI 1584862, a potential first-in-class oral compound for the treatment of geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD)1; and BI 771716, an antibody fragment, respectively. BI 1584862 is a phospholipid modulator intended to preserve patient vision by targeting inflammation and preserving vascular function.
Bausch + Lomb's LuxLife IOL receives CE Mark approval in Europe

1 week ago | optometrytimes.com | Jordana Joy

Bausch + Lomb has announced CE Mark approval for its LuxLife full range of vision intraocular lens (IOL).1 The preloaded, non-diffractive IOL utilizes Pure Refractive Optics (PRO) technology in order to provide continuous vision for the entire optical diameter and from distance to near, according to a news release.
Anthem Blue Cross, Blue Shield approves coverage for amblyopia treatment from Luminopia

1 week ago | optometrytimes.com | Emily Kaiser Maharjan

Today, Luminopia announced that its amblyopia treatment has been approved by Anthem Blue Cross and Blue Shield for insurance coverage.1 The news comes on the heels of the FDA’s age extension of clearance for Luminopia’s amblyopia treatment, now indicating treatment from patients aged 4 to 7 to patients aged 4 to 12 years.2 Both are steps toward expanding access to the unique, entertainment-based amblyopia treatment nationwide.
ARVO 2025: Head-scanning training program improves blind-side detection during virtual driving for hemianopia patients

1 week ago | optometrytimes.com | Lynda Charters

Yi Ni Toh, PhD, and colleagues reported that head-scanning training for patients with hemianopia improved the rates of detection of blind-side hazards, speed of detection of blind-side hazards, and safety during virtual driving. She reported their findings at the Association for Research in Vision and Ophthalmology 2025 annual meeting in Salt Lake City.